{"entity":{"id":"nct03260894","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","aka":["KEYNOTE-679"],"tldr":"A phase 3 trial of Pembrolizumab, Epacadostat, Sunitinib and Pazopanib in Renal cell carcinoma, run by Incyte Corporation, completed.","summary":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) is a phase 3 interventional study registered as NCT03260894 by Incyte Corporation, with 129 participants recorded, started 2017-12-07 and reaching its primary completion in 2018-08-22. Interventions recorded: Pembrolizumab, Epacadostat, Sunitinib, Pazopanib. Conditions recorded: Renal Cell Carcinoma (RCC).\n\nLinked to the drug Epacadostat because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03260894","url":"https://clinicaltrials.gov/study/NCT03260894"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","epacadostat","sunitinib","pazopanib"],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03260894","phase":"3","setting":"A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)","sponsor":"Incyte Corporation","started":"2017-12-07","startedType":"actual","yearReported":2019,"enrolled":129,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC), Objective Response (CR+PR)","primary":true,"unit":"%","arms":[{"name":"Pembrolizumab + Epacadostat","n":64,"value":31.3,"note":"95% CI 20.2 to 44.1; Figures from the ClinicalTrials.gov results section (first posted 2019-09-10), not from a publication"},{"name":"SoC (Sunitinib or Pazopanib)","n":65,"value":29.2,"note":"95% CI 18.6 to 41.8"}],"source":"https://clinicaltrials.gov/study/NCT03260894?tab=results"}]},"route":"/trials/nct03260894/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"epacadostat","kind":"drug","name":"Epacadostat","route":"/drugs/epacadostat/"},{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}]}}